<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT03239353</url>
  </required_header>
  <id_info>
    <org_study_id>UAP008C001</org_study_id>
    <nct_id>NCT03239353</nct_id>
  </id_info>
  <brief_title>A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of Entecavir Extended Release (XR) in Healthy Subjects</brief_title>
  <official_title>A Phase 1, Randomized, Partially-Blind, Parallel-Group, Active and Placebo Controlled Study to Evaluate the Safety and Pharmacokinetics of Single Oral Doses of Entecavir Extended Release (XR) in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aucta Pharmaceuticals, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aucta Pharmaceuticals, Inc</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase 1, randomized, parallel-group, single-center study in healthy adult subjects.&#xD;
      The study will be conducted in two parts sequentially:&#xD;
&#xD;
      Part 1 is an open-label, two-arm, active-controlled design to evaluate the PK and safety of&#xD;
      single oral dose of ETV XR tablet (1.5 mg) in healthy subjects. Part 1 will consist of 16&#xD;
      healthy subjects.&#xD;
&#xD;
      Part 2 is a double-blind, three-arm, placebo-controlled design to evaluate the PK and safety&#xD;
      of higher oral doses of ETV XR tablet (3 mg and 6 mg) in healthy subjects. Part 2 will&#xD;
      consist of 24 healthy subjects.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 20, 2017</start_date>
  <completion_date type="Actual">June 20, 2018</completion_date>
  <primary_completion_date type="Actual">May 29, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To characterize the Pharmacokinetics (PK) of ETV XR tablet after single oral doses in healthy subjects.</measure>
    <time_frame>22 days</time_frame>
    <description>Peak Plasma Concentration(Cmax)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To characterize the Pharmacokinetics (PK) of ETV XR tablet after single oral doses</measure>
    <time_frame>22 days</time_frame>
    <description>Area under the plasma concentration versus time curve (AUC)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To characterize the Pharmacokinetics (PK) of ETV XR tablet after single oral doses</measure>
    <time_frame>22 days</time_frame>
    <description>peak time (Tmax)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To characterize the Pharmacokinetics (PK) of ETV XR tablet after single oral doses</measure>
    <time_frame>22 days</time_frame>
    <description>Relative bioavailability (Frelative)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To characterize the Pharmacokinetics (PK) of ETV XR tablet after single oral doses</measure>
    <time_frame>22 days</time_frame>
    <description>half life (t1/2)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To assess ETV XR tablet in healthy subjects.</measure>
    <time_frame>22 days</time_frame>
    <description>adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess ETV XR tablet in healthy subjects.</measure>
    <time_frame>22 day</time_frame>
    <description>laboratory abnormalities</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess ETV XR tablet in healthy subjects.</measure>
    <time_frame>22 days</time_frame>
    <description>vital signs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess ETV XR tablet in healthy subjects.</measure>
    <time_frame>22 days</time_frame>
    <description>12-lead electrocardiograms (ECGs)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the dose linearity of ETV XR tablet</measure>
    <time_frame>60 days</time_frame>
    <description>1.5mg, 3mg and 6mg PK linearity</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>HBV</condition>
  <arm_group>
    <arm_group_label>1.5 mg ETV XR tablet</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>3 mg ETV XR tablet</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>6 mg ETV XR tablet</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo-to-match 1.5 mg ETV XR tablet</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>0.5 mg ETV IR tablet</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Entecavir</intervention_name>
    <description>Study drug (entecavir or placebo) will be administered with 240 mL of water following an overnight fast (no food or drink, except water, for at least 10 hours). Subjects will be required to fast (no food or beverages other than water) until after collection of the 4-hour blood draw.</description>
    <arm_group_label>0.5 mg ETV IR tablet</arm_group_label>
    <arm_group_label>1.5 mg ETV XR tablet</arm_group_label>
    <arm_group_label>3 mg ETV XR tablet</arm_group_label>
    <arm_group_label>6 mg ETV XR tablet</arm_group_label>
    <arm_group_label>Placebo-to-match 1.5 mg ETV XR tablet</arm_group_label>
    <other_name>placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
        Subjects will be considered for enrollment in the study if they meet all of the inclusion&#xD;
        criteria and none of the exclusion criteria.&#xD;
&#xD;
          1. Male or female aged between 18 and 55 years (inclusive). Body weight ≥ 50 kg for&#xD;
             males, and ≥45 kg for females and Body Mass Index (BMI) between 18 and 28 kg/m2&#xD;
             (inclusive), BMI(kg/m2) = body weight(kg)/{height(m)}2;&#xD;
&#xD;
          2. Ability to fully understand the purpose, characteristic, method and the possible&#xD;
             adverse effects of the trial, and voluntarily signed Informed Consent obtained before&#xD;
             any trial-related procedures are performed;&#xD;
&#xD;
          3. Ability to comply with the requirements of this trial protocol, including refrain from&#xD;
             strenuous exercise/activity 3 days prior to Day -1 (admission) and for 3 days prior to&#xD;
             the Day 8, Day 15 and the final follow-up visit on Day 22through the duration of the&#xD;
             study&#xD;
&#xD;
          4. Have a creatinine clearance (CLCr) ≥ 80 mL/min;&#xD;
&#xD;
          5. Male subjects and female subjects of child bearing potential must be willing to&#xD;
             practice effective contraception during the study and been willing and able to&#xD;
             continue contraception for 90 days after their dose of the study treatment;&#xD;
&#xD;
          6. Male subjects must refrain from sperm donation from Day -1 through completion of the&#xD;
             study and continuing for at least 90 days from the date of last dose of study drug;&#xD;
&#xD;
          7. Subjects must refrain from blood donation from Screening through completion of the&#xD;
             study and continuing for at least 30 days from date of last dose of study drug;&#xD;
&#xD;
          8. AST, ALT and bilirubin ≤ 1.5xULN (isolated bilirubin &gt; 1.5xULN is acceptable if&#xD;
             bilirubin is fractionated and direct bilirubin &lt;35%);&#xD;
&#xD;
          9. Must, in the opinion of the Investigator, be in good health based upon medical&#xD;
             history, physical examination (including vital signs), and screening laboratory&#xD;
             evaluations (hematology, chemistry, and urinalysis must fall within the normal range&#xD;
             of the central laboratory reference ranges unless the results have been determined by&#xD;
             the Investigator to have no clinical significance).&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
        A subject meeting any of the following criteria will be excluded from the study:&#xD;
&#xD;
          1. Current or a history of any clinically significant medical illness or medical&#xD;
             disorders the investigator considers should exclude including (but not limited to)&#xD;
             neurological disease, cardiovascular disease, hepatic or renal disease,&#xD;
             gastrointestinal tract disease (such as dysphagia, gastrointestinal ulcers),&#xD;
             respiratory disease, metabolism, skeletal system diseases or other condition known to&#xD;
             interfere with absorption, distribution, metabolism, or excretion of drugs;&#xD;
&#xD;
          2. Has a positive result from serology examination for hepatitis B virus (HBV), hepatitis&#xD;
             C virus (HCV), or human immunodeficiency virus (HIV);&#xD;
&#xD;
          3. There are drug-dependent or drug abuse history, or urine drug abuse screening&#xD;
             positive;&#xD;
&#xD;
          4. Subject smoked more than 5 cigarettes or other tobacco or nicotine-containing products&#xD;
             within 1 month prior to dosing and is unwilling to abstain from smoking for 48 hours&#xD;
             prior to check-in (Day -1)ing, for the duration of the confinement period and at each&#xD;
             follow-up visit;&#xD;
&#xD;
          5. Has used an alcohol consumption of more than 14 units of alcohol per week (1 unit of&#xD;
             alcohol is equivalent to 360 mL of beer or 45 mL of spirits with 40 % of alcohol or&#xD;
             150 mL of wine) within 6 months prior to screening or taking products containing&#xD;
             alcohol 48 hours prior to IMP administration;&#xD;
&#xD;
          6. Participated in any drug or medical device clinical trial within 3 months prior to&#xD;
             screening;&#xD;
&#xD;
          7. Pregnant or breastfeeding women or pregnancy testing is positive;&#xD;
&#xD;
          8. Have taken any prescription medications, over-the-counter medications, supplements or&#xD;
             herbal products within 14 days, or 5 half-lives (whichever is longer), of study drug&#xD;
             dosing, with the exception of paracetamol and hormonal contraceptive medications,&#xD;
             unless in the opinion of the Investigator and/or Medical Monitor that the substance&#xD;
             would not have any material impact on participant safety or the quality of study data;&#xD;
&#xD;
          9. Donated blood greater than 400 mL or significant blood loss equivalent to 400 mL or&#xD;
             received blood transfusion within 3 months of screening; Or donated blood greater than&#xD;
             200 ml or significant blood loss equivalent to 200 mL within 1 months prior to&#xD;
             screening;&#xD;
&#xD;
         10. Has infectious diseases within four weeks at screening (in the opinion of the&#xD;
             investigator would pose a risk for participation in this study), severe trauma, or a&#xD;
             history of major surgery within 3 months;&#xD;
&#xD;
         11. Cannot tolerate venepuncture or cannulation;&#xD;
&#xD;
         12. Consumption of grapefruit, grapefruit juice, cranberries, or products containing&#xD;
             Seville oranges (fruit juices, marmalade, jam, etc) within 7 days prior to study drug&#xD;
             dosing; consumption of caffeine-containing products within 48 hours of study drug&#xD;
             dosing;&#xD;
&#xD;
         13. Have been vaccinated within 90 days of study dosing, with the exception of licensed&#xD;
             intranasal or intramuscular influenza vaccine ≤ 14 days prior to dosing.&#xD;
&#xD;
         14. Have severe multiple allergies and / or severe allergies (including latex / heparin&#xD;
             allergy) history, or has hypersensitivity or significant intolerance to prescription&#xD;
             drugs or over-the-counter drugs or food;&#xD;
&#xD;
         15. Subjects who, in the opinion of the Investigator, should not participate in the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Linear Clinical Research Ltd</name>
      <address>
        <city>Nedlands</city>
        <state>Western Australia</state>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>June 2018</verification_date>
  <study_first_submitted>July 27, 2017</study_first_submitted>
  <study_first_submitted_qc>August 1, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 4, 2017</study_first_posted>
  <last_update_submitted>June 25, 2018</last_update_submitted>
  <last_update_submitted_qc>June 25, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">June 27, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Entecavir</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT03239353
org study id: UAP008C001
nct id: NCT03239353
lead sponsor: 
has dmc: Yes
is fda regulated drug: No
is fda regulated device: No
is us export: No
This is a phase 1, randomized, parallel-group, single-center study in healthy adult subjects.
      The study will be conducted in two parts sequentially:

      Part 1 is an open-label, two-arm, active-controlled design to evaluate the PK and safety of
      single oral dose of ETV XR tablet (1.5 mg) in healthy subjects. Part 1 will consist of 16
      healthy subjects.

      Part 2 is a double-blind, three-arm, placebo-controlled design to evaluate the PK and safety
      of higher oral doses of ETV XR tablet (3 mg and 6 mg) in healthy subjects. Part 2 will
      consist of 24 healthy subjects.
allocation: Randomized
intervention model: Parallel Assignment
primary purpose: Treatment
masking: Double (Participant, Care Provider)
measure: To characterize the Pharmacokinetics (PK) of ETV XR tablet after single oral doses in healthy subjects.
time frame: 22 days
description: Peak Plasma Concentration(Cmax)
measure: To characterize the Pharmacokinetics (PK) of ETV XR tablet after single oral doses
time frame: 22 days
description: Area under the plasma concentration versus time curve (AUC)
measure: To characterize the Pharmacokinetics (PK) of ETV XR tablet after single oral doses
time frame: 22 days
description: peak time (Tmax)
measure: To characterize the Pharmacokinetics (PK) of ETV XR tablet after single oral doses
time frame: 22 days
description: Relative bioavailability (Frelative)
measure: To characterize the Pharmacokinetics (PK) of ETV XR tablet after single oral doses
time frame: 22 days
description: half life (t1/2)
measure: To assess ETV XR tablet in healthy subjects.
time frame: 22 days
description: adverse events
measure: To assess ETV XR tablet in healthy subjects.
time frame: 22 day
description: laboratory abnormalities
measure: To assess ETV XR tablet in healthy subjects.
time frame: 22 days
description: vital signs
measure: To assess ETV XR tablet in healthy subjects.
time frame: 22 days
description: 12-lead electrocardiograms (ECGs)
measure: To evaluate the dose linearity of ETV XR tablet
time frame: 60 days
description: 1.5mg, 3mg and 6mg PK linearity
arm group label: 1.5 mg ETV XR tablet
arm group type: Active Comparator
arm group label: 3 mg ETV XR tablet
arm group type: Active Comparator
arm group label: 6 mg ETV XR tablet
arm group type: Active Comparator
arm group label: Placebo-to-match 1.5 mg ETV XR tablet
arm group type: Placebo Comparator
arm group label: 0.5 mg ETV IR tablet
arm group type: Other
intervention type: Drug
intervention name: Entecavir
description: Study drug (entecavir or placebo) will be administered with 240 mL of water following an overnight fast (no food or drink, except water, for at least 10 hours). Subjects will be required to fast (no food or beverages other than water) until after collection of the 4-hour blood draw.
arm group label: 0.5 mg ETV IR tablet
arm group label: 1.5 mg ETV XR tablet
arm group label: 3 mg ETV XR tablet
arm group label: 6 mg ETV XR tablet
arm group label: Placebo-to-match 1.5 mg ETV XR tablet
other name: placebo
criteria: 
gender: All
minimum age: 18 Years
maximum age: 55 Years
healthy volunteers: Accepts Healthy Volunteers
facility: 
country: Australia
responsible party type: Sponsor
mesh term: Entecavir
sharing ipd: No